Artiva Biotherapeutics is a clinical-stage biotech developing NK (natural killer) cell therapies, with a lead focus on B-cell driven autoimmune diseases. Artiva's lead candidate, AlloNK (AB-101), is an allogeneic, off-the-shelf NK cell therapy designed to be paired with monoclonal antibodies to deplete B-cells via a mechanism called ADCC (antibody-dependent cellular cytotoxicity). Artiva's primary target is refractory rheumatoid arthritis — patients who have failed two or more prior biologic or targeted therapies — and AlloNK is also being evaluated in Sjögren's disease, lupus, systemic sclerosis, and other autoimmune diseases across several ongoing Phase 1 and Phase 2a trials. AlloNK holds FDA Fast Track designation in refractory RA and lupus nephritis. Artiva also has two earlier-stage CAR-NK programs: AB-201, targeting HER2-expressing solid tumors, and AB-205, targeting T-cell lymphomas — both licensed from GC Cell on an ex-Asia/Pacific basis. Artiva was spun out of GC Cell, a South Korean cell therapy company, in 2019, and relies on GC Cell for underlying manufacturing IP and clinical drug supply. AlloNK is manufactured from donor cord blood, allowing bulk production and cryopreservation — unlike autologous CAR-T therapies, which are custom-made per patient. Artiva estimates AlloNK's commercial cost of goods well below autologous CAR-T therapies, and explicitly targets community rheumatology clinics rather than specialized hospital centers as the administration setting. Artiva generates no revenue and is fully funded through capital markets.